scholarly journals Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
D. Graceffa ◽  
E. Maiani ◽  
A. Pace ◽  
F. M. Solivetti ◽  
F. Elia ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Vascular Endothelial Growth Factor ◽  
Psoriatic Arthritis ◽  
Growth Factor ◽  
Malignant Glioma ◽  
Anticancer Agents ◽  
Anaplastic Oligodendroglioma ◽  
Vascular Endothelial ◽  
History Of ◽  
Endothelial Growth Factor

Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma.

Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke

Heart ◽  
2018 ◽  
Vol 105 (7) ◽  
pp. 553-558 ◽  
Author(s):  
John Berntsson ◽  
J Gustav Smith ◽  
Linda S B Johnson ◽  
Martin Söderholm ◽  
Yan Borné ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Ischaemic Stroke ◽  
Cox Regression ◽  
High Plasma ◽  
Population Based ◽  
Vascular Endothelial ◽  
History Of ◽  
Endothelial Growth Factor

ObjectiveVascular endothelial growth factor D (VEGF-D) has important functions in lymphangiogenesis and angiogenesis. High plasma levels of VEGF-D have been associated with incidence of heart failure. The association of VEGF-D with atrial fibrillation (AF) and stroke is unclear and we hypothesised that VEGF-D could also be associated with incidence of AF and ischaemic stroke.MethodsVEGF-D was measured in fasting blood samples of 4689 subjects (40% men) without a history of AF from the Malmö Diet and Cancer Study, a prospective, population-based study in Sweden. Median age was 58 years (range 46–68). Cox regression analyses, adjusted for multiple risk factors, was used to assess AF and ischaemic stroke risk in relation to VEGF-D levels.ResultsDuring a median follow-up time of 20.6 years, there were 637 cases of incident AF and 322 cases of first ischaemic stroke. After adjustment, VEGF-D was significantly associated with AF (HR 1.13(95% CI 1.04 to 1.23) per 1 SD increase) and ischaemic stroke (HR 1.14(95% CI 1.02 to 1.28) per 1 SD). The association with ischaemic stroke was explained by an increased incidence of AF-related stroke. HRs per 1 SD were 1.34 (95% CI 1.04 to 1.71) for AF-related ischaemic stroke and 1.04 (95% CI 0.90 to 1.19) for ischaemic stroke without AF.ConclusionsIncreased VEGF-D concentrations were associated with AF and ischaemic stroke. The relationship with ischaemic stroke was more pronounced in subjects with a diagnosis of AF.

Sign in / Sign up

Export Citation Format

Share Document